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http://dx.doi.org/10.1016/j.pedneo.2Background: Patients with severe osteogenesis imperfecta (OI; MIM number 259420) suffer
from low bone mass, fractures, and bone pain since birth, and have poor prognosis. This study
assessed the outcome of patients with severe OI who were treated with cyclic pamidronate
prior to the age of 1 year.
Methods: The six patients, who had bone fractures either in utero or in their 1st month of life,
were treated with cyclic pamidronate from a mean age of 2.8 months.
Results: All the patients tolerated the infusion, except for having transient hypocalcemia at
the first infusion. Decreases in irritability and improvements in feeding were observed 2e3
months after the first infusion. All patients showed a rapid increase in bone mineral density
over the first 2 years. Fractures occurred at a rate of 0.6/year. At a mean age of 6.4 years, five
patients with no interruption in treatment had normal ambulatory function, but they were
short in height.
Conclusion: Patients with neonatal OI can have a favorable outcome when treated with cyclic
pamidronate infusions early in life.
Copyright ª 2014, Taiwan Pediatric Association. Published by Elsevier Taiwan LLC. All rights
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Neonatal treatment of pamidronate in osteogenesis imperfecta 3071. Introduction
Osteogenesis imperfecta (OI; MIM number 259420) is char-
acterized by decreased bone mass, increased bone
fragility, bone pain, and frequent fractures because of
defects in the collagen genes.1 Clinical manifestations of
patients may vary from nondeforming OI with blue sclera to
lethal perinatal complications.1,2 At present, OI is classified
into eight different types and 10 disease-causing genes
have been shown to cause OI.3 The incidence rate is six to
seven/100,000 when including all types of OI.1 Most pa-
tients have an autosomal dominant inheritance with 100%
penetrance but variable clinical expression.1 In general,
patients with earlier onset of fracture have poorer
prognosis.
OI has been treated with intravenous administration of
bisphosphonates since 19874; pamidronate has been the
first and still most commonly used drug.5 The bisphospho-
nate compounds are potent inhibitors of bone resorption,
and histomorphometric studies of bone from OI patients
suggest that this disorder is associated with an increase in
osteoclastic activity and a reduction in the formation of
new bone. The therapy has been shown to decrease bone
pain, increase bone mineral density (BMD) and vertebral
body size, accelerate growth rate, and improve mobility in
patients with OI.6e12
Because bisphosphonate treatment does not correct the
defects in collagen fibers, its effect on severe patients who
have fractures at or shortly after birth has not been
confirmed. Without proper treatment, these patients either
die early in life or survive with severe bone fractures and
extremely short stature. Munns et al13 treated 29 patients
starting from a median age of 6 months. After 3 years, the
treated patients showed improved bone strength and bet-
ter gross motor function, but there was no comparison with
normal controls in either mobility or fracture. They were
also concerned about the suppression of bone turnover by
pamidronate treatment. Antoniazzi et al14 treated 10 pa-
tients diagnosed at a mean age of 33 days, starting treat-
ment either immediately or after 6 months. One year later,
those treated at birth showed improvements in biochemical
profiles and in vertebral body morphologies. Astro¨m et al15
gave monthly infusions of pamidronate to 11 patients at a
median age of 3.6 months. At a median age of 4.8 years, all
children walked but all required femoral intramedullary
rods for fractures, and five needed tibial rodding for
extreme curvatures that prevented functional standing and
walking.
We began treating newborn infants with OI with pamidr-
onate since 2001.16 In this study,we report theoutcomeof six
patients treated with pamidronate. The mean age of the
patients while starting the treatment was 2.8 months. Five
patients with no interruption in treatment obtained normal
motor, while the other one walks with walker.
2. Methods
2.1. Patients
From January 2001 to March 2013, there were six patients
diagnosed with OI who were either born with fractures orhad fractures within the 1st month of life and received
cyclic pamidronate infusions in our hospital. The diagnosis
of OI depended on clinical features including bone frac-
tures, blue sclera, family history, radiologic findings, and
BMD. Collagen Type I [COL1A1 (MIM number 120150) and
COL1A2 genes (MIM number 120160)] mutation analyses
were performed in six patients, and COL1A1 and COL1A2
mutations were found in five patients (Table 1). The study
protocol was approved by the Institutional Review Board of
our hospital (No. 201307031RINC).
2.2. Treatment protocol
The dosage and frequency of pamidronate infusion depen-
ded on age. In younger populations, the dosage was lower,
but the frequency was higher than that in older patients.
The dosing and frequency schedule was as follows: 0.5 mg/
kg every 2 months prior to 1 year of age; 1 mg/kg every 2
months between 1 year and 2 years of age; 1.5 mg/kg every
3 months between 2 years and 4 years of age; and 2 mg/kg
every 3e4 months after 4 years of age. The drug was
diluted in a 0.9% saline solution and infused over 4 hours.
Oral calcium carbonate (125 mg two times a day) and
vitamin D (cholecalciferol 400 international units daily)
were also supplied. Patient 5 was initially treated at
another hospital by a monthly infusion protocol prior to
being transferred to our hospital at 3 years of age; at that
time he still could not sit.
2.3. Data collection
Our study retrospectively collected the anthropometric,
radiological, and biochemical results from patient medical
records. We also collected data related to their symptom-
atic presentations, sex, treatment starting dates, lumbar
spine BMD results, functional assessments, biochemical
profiles, bone fracture rates, and disease complication
outcomes. The standard score (standard deviation scores or
SDS) for height was calculated based on the World Health
Organization international growth references if the patient
was aged <5 years; the Taiwanese growth curve was used if
the patient was aged >5 years.17,18 Lumbar spine (L2eL4)
BMD examinations were performed in the anteroposterior
direction with dual-energy X-ray absorptiometry (Norland
XR-26 Mark II; Norland, Fort Atkinson, WI, USA). The BMD
results were transformed into age-specific Z scores based
on reference data from Zanchetta et al19 and from normal
young Chinese in the Taipei region.20,21
3. Results
3.1. Symptom relief after pamidronate infusion
Cyclic pamidronate infusion was started prior to the age 1
year in all six patients. These patients were either born
with fractures or had fractures within the 1st month of life,
and they were all irritable and poorly fed prior to treat-
ment. Symptom relief was seen 1 month after the first
infusion. Their feeding normalized after the second
pamidronate infusion; specifically, 2e3 months after the
Table 1 Growth, fractures, and ambulation status of patients after cyclic pamidronate infusions.
Patient no. 1 2 3 4 5 6 Mean  SD
Sex F M F F M F
COL1A1 mutation c.2236-47_2273
del 85
c.1273G>A c.2497G>A *c.901G>A Not found c.769G>A
Time of first fracture In utero In utero In utero 1 mo 3 d At birth
Age at start (mo) 0.5 0.7 1.2 4.3 6.5 3.3 2.8  2.4
Starting height (SDS) 2.37 5.39 8.26 5.12 2.46 0.8 3.8  3.1
Current age (y) 12.2 0.8 1 5.4 9.3 9.5 6.4  4.8
Latest height (SDS) 4.12 7.13 6.61 4.53 4.22 4.53 5.2  1.3
Years of treatment 12.13 0.78 0.9 5.06 8.71 9.23 6.1  4.7
Fracture rate
(per year)
1.23 0 1.27 0.82 0.24 0 0.6  0.6
Mobility Walk and run,
leg length
discrepancy
Rolling over Sit with
support
Walk and
run fast
Walk with
walker
Walk and run,
leg length
discrepancy
F Z female; M Z male; SD Z standard deviation; SDS Z standard deviation scores. *COL1A2 mutation.
Figure 1 Changes in bone mineral density (BMD) in the six
patients from Group 1 after they received cyclic pamidronate
infusion. BMD is expressed as a Z score. Patients 2 and 3 had
only one BMD measurement (arrows).
308 C.-H. Lin et alfirst infusion. At that time, the babies could be handled
easier during baths or diaper changes, without triggering
irritable crying.
3.2. Hypocalcemia after cyclical pamidronate
treatment
Hypocalcemia after pamidronate infusion was observed in
all three patients receiving pamidronate during their 1st
month of life, although oral calcium and vitamin D supplies
were prescribed. Patient 1 suffered from a seizure attack 5
days after the first infusion when she was discharged from
the hospital. Her blood calcium level was 1.225 mmol/L
(normal range: 2.02e2.60 mmol/L) at the time of seizure
occurrence.16 After this experience, we monitored blood
calcium levels more closely for 3e5 days in these patients,
especially after the first infusion, and then gave aggressive
intravenous calcium supplementation (0.54 mEq/kg cal-
cium chloride by slow intravenous push every 8 hours) when
we discovered blood calcium levels lower than 2 mmol/L.
Patients 2 and 3 were noted to have respective blood cal-
cium levels of 1.97 mmol/L and 1.72 mmol/L 5 days after
the first infusion. As a result of timely management of their
hypocalcemia, no seizure occurred in these patients. As a
whole, the calcium levels of the six patients were
2.34  0.28 mmol/L prior to the first infusion and
2.19  0.29 mmol/L 3 days after the infusion, and the
phosphate levels were 5.44  0.27 mg/dL prior to the first
infusion and 4.50  0.66 mg/dL 3 days after the infusion
(both were statistically nonsignificant). Fever, bone pain
and common adverse effects of pamidronate infusion were
not seen in these patients.
3.3. Growth after cyclical pamidronate infusion
The mean age of the patients at the start of treatment was
0.2 years (median: 0.2 years), and the mean height SDS at
the start of treatment was 3.89 (median: 3.14). Their
mean height SDS after 6.1 years (median: 6.9 years) of
cyclical pamidronate treatment was 5.2 (median: 4.5).Their average lumbar spine (L2eL4) BMD increased quickly
after pamidronate infusion (Figure 1). The BMD was usually
stabilized 2e3 years after the start of treatment.
3.4. Changes in radiological features
All patients showed significant improvements in skeletal
radiological features. Patient 1 was treated and followed
for more than 12 years. Her four extremities were curved
when she was born. Radiological studies of her lower ex-
tremities performed shortly after birth revealed poor
mineralization of both the long bones and the pelvis
(Figure 2A). The cupping of the metaphysis was prominent,
and her femur and tibial bones were curved. Her skull
bones, facial bones, and vertebrae were also poorly
mineralized (Figure 2B). Radiological studies performed at
3 years of age revealed much improved bone mineralization
over the long bones and vertebrae (Figure 2C and D). Most
of her long bones were straight, and her femur bones were
only slightly curved. Radiological studies at 12 years of age
revealed straight and normally developed bones (Figure 2E
and F). However, metal plates were placed after fractures
on both femurs to increase bone strength.
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logical studies at that time revealed curved femur bones
with prominent fractures (arrow) and metaphyseal flaring
(Figure 3A). His vertebral bone development was poor. A
repeat study at 10 months of age revealed that his femurs
were straighter than previously, although both tibial bones
were slightly curved (Figure 3B). Vertebral development
was also better. Radiological studies of Patient 3 at 5 weeks
of age revealed curved bones and multiple fractures (ar-
rows) over all extremities (Figure 3A). At 10 months of age,
all fractures healed and their bone morphologies were also
much improved (Figure 3D). The radiological features of
Patient 4 were less dramatic than those seen in Patients
1e3; however, curving, fracture (arrow), and metaphyseal
flaring were all present (Figure 3E). Follow-up pictures at
both 3 years and 5 years of age (Figure 3F) showed straight
bones except for the right femur. The tibial bones still
experienced fractures, and one intramedullary rod was
placed there to strengthen the right tibial bone. In
Figure 3F, parallel high-density lines were seen in the distal
femoral and tibial metaphysis (white arrows). Each line
represents a course of pamidronate infusion; these lines are
also referred to as zebra lines. Patient 5 had more bone-
related complications because of inappropriate treatment
prior to 3 years of age, and sclerotic changes were observed
over the metaphysis at 9 years of age. Patient 6 had a
fracture over the right arm at birth.Figure 2 Radiological studies of Patient 1. (A) Curved leg bon
mineralized skull bones at 12 days of age. (C and D) Improvements
seen at 3 years of age. (E) Straight long bones with metal plates on
vertebral bodies at 12 years of age.3.5. Fracture rates and ambulation status
The mean annual fracture rate of the patients was 0.6  0.5
per year (Table 1). Internal fixation after fracture by either
a rod or plate was a common practice in these patients. The
fractures usually occurred after minor injuries; although
these fractures bothered the patients, healing was normal
and internal fixation increased their bone strength. Their
ambulation status was close to normal. All the four patients
who were older than 1 year of age walked; three of them
could run. Patient 5 was treated by a monthly cyclic infu-
sion protocol of pamidronate until 3 years of age, which
was withdrawn 9 months prior to when we treated him. Leg
length discrepancy and scoliosis occurred in Patients 1
and 6.
4. Discussion
4.1. Pamidronate infusion improves the outcome of
severe OI
Patients who have curved bones at birth or have fractures
during the 1st month of life are usually classified as Type III
OI. These patients can have severe complications and a
limited life span. In this study, cyclic pamidronate infusions
were started at 1e2 months of age, earlier than most otheres that are poorly mineralized at 12 days of age. (B) Poorly
in bone mineralization over the long bones and vertebrae are
both femurs at 12 years of age. (F) Better mineralization of the
Figure 3 Radiological studies of Patients 2e4. (A) Patient 2 showed curved femur bones with metaphyseal flaring and fractures
(arrow) at 1 month of age, and (B) improvement at 10 months of age. (C) Patient 3 showed curved bones and fractures (arrow) at 5
weeks of age, and (D) improvements at 10 months of age. (E) Patient 4 showed curving, fracture (arrow), and metaphyseal flaring at
10 months of age, and (F) straight tibial bones but with fractures at both mid shafts at 5 years of age. Zebra lines were prominent on
both the distal femur and tibia (white arrows).
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than 12 years. We saw that those patients functioned nor-
mally. Bisphosphonate infusion in neonates carries a higher
risk of hypocalcemia, but can be managed by calcium
supplementation. Although patients still had fractures
(mean 0.6 fractures/year), the fractures did not markedly
disturb their life. As a whole, early cyclic pamidronate in-
fusions changed the natural history of severe OI.4.2. Mechanisms and regimens of cyclic
bisphosphonate infusion
The OI pathological process results from defective collagen
fibers that cause excessive bone material destruction and
absorption.22 Bisphosphonates decrease the bone material
absorption and increase the bone density in OI patients.13,23
The 2e4-month cyclic infusion protocol design is based on
the long biological half-life of pamidronate and allows bonegrowth between infusions.5,7,13,14 Monthly infusion of
bisphosphonates6,15 may not allow enough time for bone
remodeling, which could be one of the reasons of bowling
tibias in the study by Astro¨m et al.15 However, in view of
the faster bone metabolism in infants, we and others13 used
a 2-month infusion regimen for infants.
Most studies used a pamidronate dosage of 4e9 mg/kg/
year,5,7,13,24 although a dose up to 12 mg/kg/year or
monthly injections have also been described9,25; however,
Senthilnathan et al reported that infants receiving 12 as
opposed to 6 mg/kg/year pamidronate had increased spine
bone density. We used a smaller total annual dose (3 mg/
kg/day) than in other protocols for patients younger than 1
year, but still obtained a result similar to that in other
studies. Because the three consecutive daily infusions
treatment protocol is not convenient for patients, we
pooled the three daily doses into a single infusion. We
found that patients tolerated this regimen very well, and
most infusions could be executed in the day clinics.
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Untreated patients with severe OI are usually very short,
due to a combination of poor bone growth, fractures and
curving of long bones, and vertebral body compression
fractures. Zeitlin et al8 have shown that pamidronate
therapy increases the height SDS in Type III OI. Unfortu-
nately, in this study, height SDS decreased during the
treatment periods. However, the four older patients were
all with a height SDS of around 4, better than the patients
described in the study by Zeitlin et al.8 Our patients had
straight legs and there was no vertebral body collapse. The
dense zebra lines were evenly spaced and might increase
bone strength. Nevertheless, we will need to further
improve treatment, and a final solution will depend on new
treatments specific to the disease etiology.
4.4. Limitations of the study
Our study has several limitations, such as lack of controls,
small number of cases, and the presence of clinical hetero-
geneity, for example, some patients had in utero fractures
whereas others had postnatal fractures. Therefore, the re-
sults from this study need to be compared with historical
cohorts. Subsequent studiesmay require further subgrouping
of disease severity to elucidate the treatment effect.
5. Conclusion
In conclusion, we demonstrated that patients with severe
OI can have a favorable outcome when treated with cyclic
pamidronate infusions in early infancy.
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